Holen Sie sich die Stockscreener-App
5.2395
0.00%
0.00
Schlusskurs vom Vortag:
$5.2395
Offen:
$5.47
24-Stunden-Volumen:
59,788
Relative Volume:
1.80
Marktkapitalisierung:
$10.04M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-47.73M
KGV:
-0.3639
EPS:
-14.3996
Netto-Cashflow:
$-13.18M
1W Leistung:
-25.94%
1M Leistung:
-34.53%
6M Leistung:
-49.74%
1J Leistung:
-71.97%
1-Tages-Spanne:
$5.12
$5.9597
1-Wochen-Bereich:
$4.9101
$7.14
52-Wochen-Spanne:
$4.9101
$34.25
Gt Biopharma Inc Stock (GTBP) Company Profile
Firmenname
Gt Biopharma Inc
Sektor
Branche
Telefon
(800) 304-9888
Adresse
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP vs PSNYW, GOODO, SHMD, CHAD, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
PSNYW
Polestar Automotive Holding Uk
|
4.29 | 773.76M | 2.07B | -1.42B | -1.37B | -0.6765 |
GOODO
Gladstone Commercial Corporation
|
20.35 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
3.33 | 220.96M | 52.15M | -21.46M | 0 | -0.4675 |
CHAD
Direxion Daily CSI 300 China A
|
7.8954 | 197.39M | 0 | 0 | 0 | 0.00 |
DWLD
Davis Select Worldwide ETF
|
46.62 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Eingeleitet | ROTH MKM | Buy |
| 2021-05-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-13 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-17 | Eingeleitet | ROTH Capital | Buy |
Gt Biopharma Inc Aktie (GTBP) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
GT Biopharma (GTBP) Slides 10.95% to $0.25 as Bearish Momentum BuildsSuperTrend - siam.in
GT Biopharma Implements Reverse Stock Split, Streamlines Capital Structure - TipRanks
GTBP stock holds steady as GT Biopharma advances TriKE cancer pipeline - AD HOC NEWS
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes - Eastern Progress
GT Biopharma Inc (NASDAQ: GTBP) Share Price, GTBP Stock News, GTBP Share Price & Updates - Kalkine
Stock Quotes, Business News and Data from Stock Markets | MSN Money - MSN
GTBP Q1 2026 Earnings: EPS Misses Estimates as Stock Drops 3.72%Dividend Cut Risk - vinanet.vn
GT Biopharma Shareholders Approve Reverse Split and Incentive Plan - TipRanks
GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes - Stock Titan
GT Biopharma Q2 Results: Net Loss Falls To $4.5 Million - scanx.trade
Gt Biopharma Reports Second Quarter 2026 Financial Results - TradingView
GTBP: Q2 2026 net loss narrowed to $4.5M as clinical programs advance and cash runway extends to Q4 2026 - TradingView
GT Biopharma Reports Second Quarter 2026 Financial Results - The Manila Times
GT Biopharma (GTBP) cuts net loss but flags going concern and Nasdaq risk - Stock Titan
GTBP Q1 2026 Earnings: Wider Loss Misses Estimates as Clinical Investment ContinuesEarnings Stability Report - vinanet.vn
GT Biopharma Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
GT Biopharma Inc (GTBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GT Biopharma Inc (GTBP) Stock News Today - TradingKey
GT Biopharma’s TriKE® Program: Pipeline, Progress, & What’s Ahead - smallcapasia.com
GTBP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
GTBP Q1 2026 Earnings: Wider Loss Misses Estimates as Clinical-Stage Pipeline AdvancesEstimate Accuracy - vinanet.vn
GT Biopharma (GTBP) Slips 4.65% to $0.29, Testing Critical Support Near $0.28Trend Reversal Picks - dars.gov.et
GT BIOPHARMA INC (GTBP) Stock Chart - ChartMill
GTBP Q1 2026 Earnings: Wider-than-Expected Loss Amid Ongoing R&D InvestmentProfit Growth Outlook - vinanet.vn
GT Biopharma Edges Higher as Biotech Sector Sees Renewed Interest — GTBP Hovers Near Key LevelsSmart Beta Flow - po-news-eg.net
GT Biopharma Inc (GTBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GT Biopharma Inc (GTBP) Cash Flow - TradingKey
GT Biopharma Inc (GTBP) Income Statement - tradingkey.com
GTBP|GT Biopharma Inc|Price:0.335|Chg%:+0.011 - TradingKey
GT Biopharma Inc (GTBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GTBP|GT Biopharma Inc|Price:0.310|Chg%:-0.011 - TradingKey
GT Biopharma Inc (GTBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GT Biopharma Inc (GTBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
GT Biopharma Inc (GTBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GTBP|GT Biopharma Inc|Price:0.324|Chg%:-0.011 - TradingKey
GT Biopharma Shares Decline 3.25% as Stock Tests Key Support at $0.30Zero Gamma Level - vinanet.vn
GT Biopharma(GTBP) Stock Options Chain | Quotes & News - Moomoo
GT Biopharma, Inc. Revenue Breakdown – NASDAQ:GTBP - TradingView
GT Biopharma Inc (GTBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Price to earnings forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
Price to earnings forward of GT Biopharma Inc – SWB:OXIA - TradingView
GT Biopharma (GTBP) Declines 3.96% as Stock Nears Critical $0.32 Support LevelVolume Weighted Price - vinanet.vn
Immunotherapy Breakthroughs Propel Clinical Momentum Ahead of ESMO Congress - Baystreet.ca
GTBP Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Ongoing Pre-Revenue StageTrough Earnings Signal - vinanet.vn
GT Biopharma (GTBP) Slides to $0.42 Amid Continued Selling PressureRetracement Entry - dars.gov.et
GT Biopharma (GTBP) Revenue BreakdownMain Composition - Moomoo
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs - Newswire Canada
GTBP News | GT BIOPHARMA INC (NASDAQ:GTBP) - ChartMill
GT Biopharma (GTBP) plans reverse stock split and larger 2022 incentive plan - Stock Titan
Enterprise value to EBITDA forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
Finanzdaten der Gt Biopharma Inc-Aktie (GTBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):